Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: Rexin-G, Epeius Biotechnologies.

Michael Morse1

  • 1Duke University Medical Center, Division of Medical Oncology, Box 3233 Room 3803, Red Zone, Duke South Clinics, Durham, NC 27710, USA. m.morse@cgct.duke.edu

Current Opinion in Molecular Therapeutics
|April 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanism of SARS-CoV-2 Nucleocapsid Protein Phosphorylation-Induced Functional Switch.

Viruses·2026
Same author

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity.

Science immunology·2025
Same author

MDS PD e-Diary: A New Patient-Centered Digital Tool in Development for People with Parkinson's Disease.

Movement disorders clinical practice·2025
Same author

Feasibility of Remote Delivery of Agitation Management Training to Psychiatry Residents in Conflict Zones.

Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·2025
Same author

Single-molecule measurements of double-stranded DNA condensation.

Biophysical journal·2025
Same author

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd).

Nature communications·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Rexin-G, an injectable retroviral vector, targets tumors with a mutant cyclin G1 gene for metastatic cancer treatment. This novel therapy is currently in phase I/II clinical trials.

Area of Science:

  • Oncology
  • Gene Therapy
  • Virology

Background:

  • Metastatic cancer presents significant treatment challenges.
  • Targeted gene delivery offers a promising therapeutic strategy.
  • Retroviral vectors are utilized for gene delivery in cancer research.

Purpose of the Study:

  • To evaluate the potential of Rexin-G as a treatment for metastatic cancer.
  • To investigate the efficacy of a tumor-targeted, injectable retroviral vector.
  • To assess the safety and feasibility of Rexin-G in early-phase clinical trials.

Main Methods:

  • Rexin-G, a retroviral vector, delivers a mutant cyclin G1 gene.
  • The vector is designed to be pathotropic, targeting tumor cells.
  • Administration is via injection, with ongoing phase I/II clinical trials.

Related Experiment Videos

Main Results:

  • Preliminary data from phase I/II trials are being collected.
  • The study focuses on the therapeutic potential in patients with metastatic cancer.
  • Further results are pending the completion of ongoing clinical evaluations.

Conclusions:

  • Rexin-G represents a novel approach to metastatic cancer therapy.
  • Tumor-targeted gene delivery via retroviral vectors warrants further investigation.
  • The ongoing clinical trials will determine the ultimate clinical utility of Rexin-G.